H.R.4857, Ensuring Equal Access to Treatments Act of 2014; H.R. 3230, Veterans Access, Accountability Act of 2014, provisions related to prescription drug services.
Duration: January 1, 2008
to
November 30, 2014
General Issues: Health Issues , Trade (Domestic & Foreign) , Medicare/Medicaid , Government Issues , Telecommunications
Spending: about $1,480,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate, U.S. Senate,, Health & Human Services - Dept of (HHS), House of Representatives,
Related Foreign Entities:
Astellas Pharma, Inc. (Tokyo, JPN); contribution to lobbying: $0; ownership 99%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2014
ML STRATEGIES, LLC terminated an engagement in which they represented Astellas Pharma US, Inc. on Jan. 20, 2015.
Original Filing: 300701724.xml
Lobbying Issues
H.R.4857, Ensuring Equal Access to Treatments Act of 2014; H.R. 3230, Veterans Access, Accountability Act of 2014, provisions related to prescription drug services.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 16, 2014.
Original Filing: 300678058.xml
Lobbying Issues
H.R. 4857, Ensuring Equal Access to Treatments Act of 2014; H.R. 3230, Veterans Access, Choice and Accountability Act of 2014, provisions related to prescription drug services.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 18, 2014.
Original Filing: 300660837.xml
Lobbying Issues
H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2014; H.R. 4857, Ensuring Equal Access to Treatments Act of 2014
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 17, 2014.
Original Filing: 300639434.xml
Lobbying Issues
Issues relating to the implementation of the Affordable Care Act; issues relating to the implementation of the Generating Antibiotic Incentives Now (GAIN) Act; H.R. 4302, Protecting Access to Medicare Act; H.R. 1801, Cancer Drug Coverage Parity Act; issues relating to the 2014 Hospital Outpatient Prospective Payment System; H.R. 4187, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2014
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 21, 2014.
Original Filing: 300623759.xml
Lobbying Issues
Issues relating to the implementation of the Affordable Care Act; issues relating to the implementation of the Generating Antibiotic Incentives Now (GAIN) Act; H.R. 1801, Cancer Drug Coverage Parity Act; issues relating to the 2014 Hospital Outpatient Prospective Payment System.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 17, 2013.
Original Filing: 300596172.xml
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; H.R. 3204, Drug Quality and Security Act; Issues relating to oncology; Issues relating to 2014 Hospital Outpatient Prospective Payment System.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 19, 2013.
Original Filing: 300577259.xml
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; S. 957, Drug Supply Chain Security Act; H. R. 1919, Safeguarding America's Pharmaceuticals Act of 2012; Issues relating to oncology; Issues relating to cardiac imaging; Issues relating to health and science education.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 17, 2013.
Original Filing: 300551516.xml
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; Issues related to drug safety and drug shortages; Issues relating to oncology.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Miscellaneous Tariff Bill (MTB).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2012
In Q4, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 18, 2013.
Original Filing: 300532895.xml
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; Issues related to drug safety and drug shortages.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Miscellaneous Tariff Bill (MTB).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2012
In Q3, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 18, 2012.
Original Filing: 300513292.xml
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; S. 3187, Food and Drug Administration Safety and Innovation Act, Title VIII, Generating Antibiotic Incentives Now; Issues related to drug safety and drug shortages.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 18, 2012.
Original Filing: 300510847.xml
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; S. 3187, Food and Drug Administration Safety and Innovation Act, Title VIII, Generating Antibiotic Incentives Now; Issues related to drug safety and drug shortages.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 18, 2012.
Original Filing: 300487527.xml
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; H. R. 5651, Food and Drug Administration Reform Act and S. 3187, Food and Drug Administration Safety and Innovation Act, Title VIII, Generating Antibiotic Incentives Now; H. R. 2182 and S. 1734, the Generating Antibiotic Incentives Now (GAIN) Act; Issues related to drug safety and drug shortages.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 18, 2012.
Original Filing: 300463564.xml
Lobbying Issues
General issues pertaining to funding levels for Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; H. R. 2182 and S. 1734, the Generating Antibiotic Incentives Now (GAIN) Act; Issues pertaining to cancer research and treatment; Issues pertaining to drug safety and drug shortages; Issues pertaining to the reauthorization of the Prescripton Drug User Free Act (PDUFA); Issues pertaining to the development of new antibiotics.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 19, 2012.
Original Filing: 300443346.xml
Lobbying Issues
General issues pertaining to funding levels for Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; H. R. 2182, the Generating Antibiotic Incentives Now (GAIN) Act; S.99, American Medical Isotope Production Act; Issues pertaining to cancer research and treatment; Issues pertaining to drug safety; Issues pertaining to the reauthorization of the Prescripton Drug User Free Act (PDUFA); Issues pertaining to the development of new antibiotics.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 19, 2011.
Original Filing: 300419250.xml
Lobbying Issues
General issues pertaining to funding levels for Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; H. R. 2182, the Generating Antibiotic Incentives Now (GAIN) Act; S.99, American Medical Isotope Production Act; Issues pertaining to cancer research and treatment; Issues pertaining to drug safety; Issues pertaining to the reauthorization of the Prescripton Drug User Free Act (PDUFA); Issues pertaining to the development of new antibiotics.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 15, 2011.
Original Filing: 300390850.xml
Lobbying Issues
General issues pertaining to funding levels for Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; H. R. 2182, the Generating Antibiotic Incentives Now (GAIN) Act; S.99, American Medical Isotope Production Act; Issues pertaining to cancer research and treatment; Issues pertaining to drug safety; Issues pertaining to the reauthorization of the Prescripton Drug User Free Act (PDUFA); Issues pertaining to the development of new antibiotics; General issues pertaining to Personalized Medicine.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 14, 2011.
Original Filing: 300363466.xml
Lobbying Issues
General issues pertaining to funding levels for Medicare and Medicaid.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to the implementation of the Affordable Health Care Act; Issues pertaining to the development of new antibiotics; S.99, American Medical Isotope Production Act; Issues pertaining to cancer research and treatment; Issues pertaining to drug safety.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Jan. 18, 2011.
Original Filing: 300340979.xml
Lobbying Issues
H. R. 1458, and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act; General issues pertaining to immunosupressives.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 2400, Strategies to Address Antimicrobial Resistance (STARR) Act; H. R. 6331, GAIN Act; Issues pertaining to the development of new antibiotics; H. R. 3276, American Medical Isotope Production Act; H. R. 6224, 21st Century ALERT Act; Issues pertaining to the orphan drug exemption to the 340 (B) program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 6517, Omnibus Trade Act of 2010, miscellaneous trade provisions.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2010
In Q3, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on Oct. 18, 2010.
Original Filing: 300315823.xml
Lobbying Issues
H. R. 1458, and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 5175 and S. 3295, DISCLOSE Act; Issues pertaining to the campaign activities of certain domestic corporations.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 2400, Strategies to Address Antimicrobial Resistance (STARR) Act; H. R. 6331, GAIN Act; Issues pertaining to the development of new antibiotics; H. R. 3276, American Medical Isotope Production Act; H. R. 6224, 21st Century ALERT Act; Issues pertaining to the orphan drug exemption to the 340 (B) program; H. R. 6389, issues pertaining to prostate cancer diagnosis and treatment; Issues pertaining to overactive bladder syndrome..
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on July 14, 2010.
Original Filing: 300286082.xml
Lobbying Issues
Issues related to CPT codes for Myocardial Perfusion Imaging; H. R. 4371; H. R. 1458, and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act; H. R. 574 & S. 254, Medicare Home Infusion Therapy Coverage Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 5175 and S. 3295, DISCLOSE Act; Issues pertaining to the campaign activities of certain domestic corporations.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 2400, Strategies to Address Antimicrobial Resistance (STARR) Act; Issues pertaining to the development of new antibiotics; H. R. 3276, American Medical Isotope Production Act, 21st Century ALERT (Access to Life-Saving Early Detection, Research and Treatment) Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $50,000. The report was filed on April 13, 2010.
Original Filing: 300256639.xml
Lobbying Issues
Issues related to CPT codes for Myocardial Perfusion Imaging; H. R. 4371; H. R. 1458, and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act; H. R. 574 & S. 254, Medicare Home Infusion Therapy Coverage Act of 2009; H. R 3962, Affordable Health Care for America Act; H. R. 3590, Patient Protection &Affordable Care Act; H. R. 4872
The Health Care and Education Reconciliation Act; issues related to immunosuppresive drug coverage & home infusion coverage.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 2221, Data Accountability and Trust Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 2400, Strategies to Address Antimicrobial Resistance (STARR) Act; H. R. 3276, American Medical Isotope Production Act, 21st Century ALERT (Access to Life-Saving Early Detection, Research and Treatment) Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, ML STRATEGIES, LLC lobbied for Astellas Pharma US, Inc. , earning $60,000. The report was filed on Jan. 19, 2010.
Original Filing: 300236785.xml
Lobbying Issues
H. R. 4371; H. R. 1458, and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act; H. R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act of 2009; H. R. 3200, America's Affordable Health Choices Act; S. 1679, Affordable Health Choices Act; H. R. 3962, Affordable Health Care for America Act; H. R. 3590, Patient Protection and Affordable Care Act; S. 1796, America's Healthy Future Act, issues related to immunosuppresive drug coverage & home infusion coverage.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 2221, Data Accountability and Trust Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 2400, Strategies to Address Antimicrobial Resistance (STARR) Act; H. R. 3276, American Medical Isotope Production Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
ML STRATEGIES, LLC amended a lobbying report for representation of Astellas Pharma US, Inc. in Q32009 on Jan. 6, 2010.
Original Filing: 300227748.xml
Lobbying Issues
H. R. 1458, and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act; H. R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act of 2009; H. R. 3200, America's Affordable Health Choices Act; S. 1679, Affordable Health Choices Act; America's Healthy Future Act; issues related to immunosuppresive drug coverage and home infusion therapy coverage.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 2400, Strategies to Address Antimicrobial Resistance (STAAR) Act; H. R. 3276, American Medical Isotope Production Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, ML STRATEGIES, LLC lobbied for Astellas Pharma, Inc. , earning $60,000. The report was filed on Oct. 15, 2009.
Original Filing: 300206029.xml
Lobbying Issues
H. R. 1458, and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act; H. R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act of 2009; H. R. 3200, America's Affordable Health Choices Act; S. 1679, Affordable Health Choices Act; America's Healthy Future Act; issues related to immunosuppresive drug coverage and home infusion therapy coverage.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H. R. 2400, Strategies to Address Antimicrobial Resistance (STAAR) Act; H. R. 3276, American Medical Isotope Production Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
ML STRATEGIES, LLC amended a lobbying report for representation of Astellas Pharma US, Inc. in Q22009 on Jan. 6, 2010.
Original Filing: 300227746.xml
Lobbying Issues
Issues relating to ensuring access to critical medications under Medicare Part D, and Medigap Policies; H. R. 1458 and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act; H. R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues pertaining to Antimicrobial Resistance; Issues pertaining to Community and Healthcare Associated Infections; Issues pertaining to organ transplantation.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, ML STRATEGIES, LLC lobbied for Astellas Pharma, Inc. , earning $60,000. The report was filed on July 15, 2009.
Original Filing: 300177916.xml
Lobbying Issues
Issues relating to ensuring access to critical medications under Medicare Part D, and Medigap Policies; H. R. 1458 and S. 565, Comprehensive Immunosuppressive Drug coverage for Transplant Patients Act; H. R. 574 and S. 254, Medicare Home Infusion Therapy Coverage Act of 2009.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues pertaining to Antimicrobial Resistance; Issues pertaining to Community and Healthcare Associated Infections; Issues pertaining to organ transplantation.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
ML STRATEGIES, LLC amended a lobbying report for representation of Astellas Pharma US, Inc. in Q12009 on Jan. 6, 2010.
Original Filing: 300227741.xml
Lobbying Issues
Issues relating to ensuring access to critical medications under Medicare Part D; Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues pertaining to Antimicrobial Resistance; Issues pertaining to Community and Healthcare Associated Infections; Issues pertaining to organ transplantation.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, ML STRATEGIES, LLC lobbied for Astellas Pharma, Inc. , earning $60,000. The report was filed on April 16, 2009.
Original Filing: 300150131.xml
Lobbying Issues
Issues relating to ensuring access to critical medications under Medicare Part D; Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues pertaining to Antimicrobial Resistance; Issues pertaining to Community and Healthcare Associated Infections; Issues pertaining to organ transplantation.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
ML STRATEGIES, LLC amended a lobbying report for representation of Astellas Pharma US, Inc. in Q42008 on Jan. 6, 2010.
Original Filing: 300227745.xml
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887 and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistyance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res. 988 and S. Res. 454 MRSA Awareness Month. S. 3560, Q1 Program Suplemental Funding Act of 2008, provisions regarding antibiotics.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, ML STRATEGIES, LLC lobbied for Astellas Pharma, Inc. , earning $60,000. The report was filed on Jan. 15, 2009.
Original Filing: 300120003.xml
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887 and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistyance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res. 988 and S. Res. 454 MRSA Awareness Month. S. 3560, Q1 Program Suplemental Funding Act of 2008, provisions regarding antibiotics.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
ML STRATEGIES, LLC amended a lobbying report for representation of Astellas Pharma US, Inc in Q32008 on Jan. 6, 2010.
Original Filing: 300227744.xml
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887. and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D; H.R. 6331, The Medicare Improvements for Patients and Providers Act; provisions relating to six classes of clinical concern under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistyance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res. 988 and S. Res. 454 MRSA Awareness Month. H. R. 6432, Animal Drug User Fee Amendments of 2008; S. 3560, Q1 Program Suplemental Funding Act of 2008, provisions regarding antibiotics.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, ML STRATEGIES, LLC lobbied for Astellas Pharma, Inc , earning $60,000. The report was filed on Oct. 16, 2008.
Original Filing: 300094195.xml
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887. and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D; H.R. 6331, The Medicare Improvements for Patients and Providers Act; provisions relating to six classes of clinical concern under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistyance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res. 988 and S. Res. 454 MRSA Awareness Month. H. R. 6432, Animal Drug User Fee Amendments of 2008; S. 3560, Q1 Program Suplemental Funding Act of 2008, provisions regarding antibiotics.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
ML STRATEGIES, LLC amended a lobbying report for representation of Astellas Pharma US, Inc in Q22008 on Jan. 12, 2010.
Original Filing: 300229406.xml
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S.1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887, and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D; S. 3101 and H.R. 6331, The Medicare Improvements for Patients and Providers Act, provisions relating to six classes of clinical concern under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res 988 and S. Res. 454 MRSA Awareness Month.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
ML STRATEGIES, LLC amended a lobbying report for representation of Astellas Pharma US, Inc in Q22008 on Jan. 6, 2010.
Original Filing: 300227743.xml
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S.1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887, and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D; S. 3101 and H.R. 6331, The Medicare Improvements for Patients and Providers Act, provisions relating to six classes of clinical concern under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res 988 and S. Res. 454 MRSA Awareness Month.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, ML STRATEGIES, LLC lobbied for Astellas Pharma, Inc , earning $60,000. The report was filed on July 16, 2008.
Original Filing: 300066752.xml
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S.1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887, and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D; S. 3101 and H.R. 6331, The Medicare Improvements for Patients and Providers Act, provisions relating to six classes of clinical concern under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res 988 and S. Res. 454 MRSA Awareness Month.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
ML STRATEGIES, LLC amended a lobbying report for representation of Astellas Pharma US, Inc in Q12008 on Jan. 6, 2010.
Original Filing: 300227740.xml
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res 988 and S. Res. 454 MRSA Awareness Month.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887, and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, ML STRATEGIES, LLC lobbied for Astellas Pharma, Inc , earning $60,000. The report was filed on May 1, 2008.
Original Filing: 300057760.xml
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res 988 and S. Res. 454 MRSA Awareness Month.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887, and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, ML STRATEGIES, LLC lobbied for Astellas Pharma, Inc , earning $60,000. The report was filed on April 18, 2008.
Original Filing: 300043130.xml
Lobbying Issues
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res 988 and S. Res. 454 MRSA Awareness Month.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887, and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2007
ML STRATEGIES, LLC filed a lobbying registration on Jan. 5, 2010 to represent Astellas Pharma US, Inc., effective July 1, 2007.
Original Filing: 300227738.xml
Issue(s) they said they’d lobby about: S. 1082 Food and Drug Administration Revitalization Act
H. R. 2900 Food and Drug Administration Amendment Act of 2007 .
3rd Quarter, 2007
ML STRATEGIES, LLC filed a lobbying registration on Dec. 3, 2009 to represent Astellas Pharma, Inc., effective July 1, 2007.
Original Filing: 300225991.xml
Issue(s) they said they’d lobby about: S. 1082 Food and Drug Administration Revitalization Act
H. R. 2900 Food and Drug Administration Amendment Act of 2007 .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...